<DOC>
	<DOCNO>NCT01299272</DOCNO>
	<brief_summary>The primary purpose study ass whether LY2216684 ( 12 mg 18 mg daily ) superior placebo adjunctive therapy selective serotonin reuptake inhibitor ( SSRI ) patient major depressive disorder ( MDD ) initially partial responder SSRI prevention re-emergence depression symptom patient MDD meet remission criterion open label treatment randomization criterion stabilization period . This trial consist two distinct period ; open label treatment period , consist two part , 8 week open label movement 10-12 week open label stabilization IF patient remission end 8 week ( open label 18 20 week total ) follow randomize blinded period 24 26 week .</brief_summary>
	<brief_title>A Study Prevention Re-emergence Depression Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Outpatients clinical diagnosis Major Depressive Disorder ( MDD ) Using reliable method birth control Are take SSRI approve MDD treatment within patient 's country SSRI prescribe , include dose , consistent label guideline within participate country Have partial response SSRI treatment Meet inclusion score predefined psychiatric scale assess diagnosis depression , disease severity , response SSRI treatment Reliable able keep schedule appointment Have least 1 previous episode MDD prior current episode within past 5 year Have currently additional ongoing Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) Axis 1 condition major depression within 1 year screen Have current previous diagnosis bipolar disorder , schizophrenia , psychotic disorder Have history substance abuse and/or dependence within past 1 year ( drug category define DSMIVTR ) , include caffeine nicotine . Have Axis II disorder , judgment investigator , would interfere compliance protocol Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia , tachyarrhythmia , narrowangle glaucoma , history urinary hesitation retention Have initiate discontinue hormone therapy ( include , birth control , thyroid hormone ) within previous 3 month prior enrollment Have lifetime history vagal nerve stimulation ( VNS ) , transcranial magnetic stimulation ( TMS ) , psychosurgery Have receive electroconvulsive therapy ( ECT ) past year Serious unstable medical condition History seizure disorder Have initiate psychotherapy , change intensity psychotherapy nondrug therapy ( acupuncture hypnosis ) within 6 week prior enrollment time study Patients , opinion investigator , judge serious risk harm self others Are pregnant breastfeed Meets criteria treatmentresistant depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>